What's new

Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024

Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024

Mar 12, 2025 - 17:37
 0
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024
Read More

Tags:

Previous Article

Farming wasn’t a wholesale success when it arrived in North Africa

Next Article

25 New Electric School Buses Unveiled At Compton, California School District

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, Indacaterol (acetate),Mometasone (furoate) (QVM149),Glycopyrronium bromide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0493/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025  0

EMEA-002329-PIP02-20-M03

EMEA-002329-PIP02-20-M03

Feb 13, 2025  0

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Krka d.d., emtricitabine,tenofovir disoproxil, Date of authorisation: 28/04/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0